A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

Journal of Affective Disorders

Volumn 167, Issue , 2014, Pages 215-223

  Ball, Susan ^a,b   Dellva, Mary Anne ^a   D'Souza, Deborah N ^c   Marangell, Lauren B ^a,d   Russell, James M ^a   Goldberger, Celine ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SYNEOS HEALTH   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjunctive treatment; Edivoxetine; Efficacy; Major depressive disorder; Norepinephrine; Safety

Indexed keywords

CITALOPRAM; EDIVOXETINE; ESCITALOPRAM; FLUOXETINE; HEMOGLOBIN; PAROXETINE; PLACEBO; SERTRALINE; ALPHA-((5-FLUORO-2-METHOXYPHENYL)METHYL)-ALPHA-(TETRAHYDRO-2H-PYRAN-4-YL)-2-MORPHOLINEMETHANOL; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; MORPHOLINE DERIVATIVE; PHENETHYL ALCOHOL; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FEMALE; HAMILTON SCALE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PULSE RATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCROTAL PAIN; SEXUALITY; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SUICIDAL BEHAVIOR; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAL SIGN; ANALOGS AND DERIVATIVES; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; SEX DIFFERENCE; SEXUAL BEHAVIOR; SUICIDAL IDEATION;

ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PHENYLETHYL ALCOHOL; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; SEXUAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 84903846446     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.06.006     Document Type: Article

References (39)

1. American Psychiatric Association (APA) Practice guideline for the treatment of patients with Major Depressive Disorder (revision) Am. J. Psychiatry 157 Suppl. 4 2000 1 45
2. C. Armstrong APA releases guidelines on treatment of patients with major depressive disorder Am. Fam. Physician 83 10 2011 1219 1227
3. L. Citrome Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 67 11 2013 1089 1104
4. P. Davey How to correct the QT interval for the effects of heart rate in clinical studies J. Pharmacol. Toxicol. Methods 48 1 2002 3 9 (Pubitemid 36577173)
5. B. Dell'Osso, M.C. Palazzo, L. Oldani, and A.C. Altamura The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects CNS Neurosci. Ther. 17 6 2011 723 732
6. S. Dubé, M.A. Dellva, M. Jones, W. Kielbasa, R. Padich, A. Saha, and P. Rao A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression J. Psychiatr. Res. 44 6 2010 356 363
7. A. Dubini, M. Bosc, and V. Polin Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning J. Psychopharmacol. 11 Suppl. 4 1997 S17 23
8. J. Endicott, J. Nee, W. Harrison, and R. Blumenthal Quality of life enjoyment and satisfaction questionnaire: a new measure Psychopharmacol. Bull. 29 2 1993 321 326 (Pubitemid 23311543)
9. M. Fava, L.M. Graves, F. Benazzi, M.J. Scalia, D.V. Iosifescu, J.E. Alpert, and G.I. Papakostas A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment J. Clin. Psychiatry 67 11 2006 1754 1759 (Pubitemid 44955157)
10. T.L. Greer, B.T. Kurian, and M.H. Trivedi Defining and measuring functional recovery from depression CNS Drugs 24 4 2010 267 284
11. W. Guy ECDEU Assessment Manual for Psychopharmacology:Revised (DHEW Publ. No. ADM 76-338) 1976 218 222 (Publisher: Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs)
12. L.L. Judd, H.S. Akiskal, J.D. Maser, P.J. Zeller, J. Endicott, W. Coryell, M.P. Paulus, J.L. Kunovac, A.C. Leon, T.I. Mueller, J.A. Rice, and M.B. Keller A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders Arch. Gen. Psychiatry 55 8 1998 694 700 (Pubitemid 28364385)
13. R.S. Keefe, H.C. Kraemer, R.S. Epstein, E. Frank, G. Haynes, T.P. Laughren, J. McNulty, S.D. Reed, J. Sanchez, and A.C. Leon Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials Innov. Clin. Neurosci. 10 Suppl. A 5-6 2013 4S 19S
14. N. Kennedy, and E.S. Paykel Residual symptoms at remission from depression: impact on long-term outcome J. Affect. Disord. 80 2-3 2004 135 144 (Pubitemid 38597136)
15. S.H. Kennedy, R.W. Lam, S.V. Parikh, S.B. Patten, and A.V. Ravindran Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorders in adults. Introduction J. Affect. Disord. 117 Suppl. 1 2009 S1 S2
16. H.C. Kraemer, E. Frank, and D.J. Kupfer How to assess the clinical impact of treatments on patients, rather than the statistical impact of treatments on measures Int. J. Methods Psychiatr. Res. 20 2 2011 63 72
17. L.S. Matza, G.A. Phillips, D.A. Revicki, L. Murray, and K.G. Malley Development and validation of a patient-report measure of fatigue associated with depression J. Affect. Disord. 134 1-3 2011 294 303
18. L.S. Matza, K.W. Wyrwich, G.A. Phillips, L.T. Murray, K.G. Malley, and D.A. Revicki The fatigue associated with depression questionnaire (FAsD): responsiveness and responder definition Qual. Life Res. 22 2 2013 351 360
19. J.A. Mauskopf, G.E. Simon, A. Kalsekar, C. Nimsch, E. Dunayevich, and A. Cameron Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder Depress. Anxiety 26 1 2009 83 97
20. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389 (Pubitemid 9136500)
21. V.M. Montori, J.P. Brito, and M.H. Murad The optimal practice of evidence-based medicine: Incorporating patient preferences into practice guidelines Journal of the American Medical Association 310 23 2013 2503 2504
22. National Institute for Health and Clinical Excellence (NICE) Depression: The Treatment and Management of Depression in Adults 2009 NICE London, England http://publications.nice.org.uk/depression-in-adults-cg90/introduction (NICE clinical guideline (CG) 90)
23. B. Pangallo, M.A. Dellva, D.N. D'Souza, B. Essink, J. Russell, and C. Goldberger A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder J. Psychiatr. Res. 45 6 2011 748 755
24. G.I. Papakostas Major depressive disorder: psychosocial impairment and key considerations in functional improvement Am. J. Manag. Care 15 Suppl. 11 2009 S316 S321
25. G.I. Papakostas, C.M. Crawford, M.J. Scalia, and M. Fava Timing of clinical improvement in the symptom resolution in the treatment of major depressive disorder Neuropsychobiology 56 2-3 2007 132 137
26. E.S. Paykel, R. Ramana, Z. Cooper, H. Hayhurst, J. Kerr, and A. Barocka Residual symptoms after partial remission: an important outcome in depression Psychol. Med. 25 6 1995 1171 1180
27. G.A. Phillips, L.S. Matza, L. Murray, and D.A. Revicki Reliability and validity of the fatigue associated with depression questionnaire (FAsD): an interim analysis Eur. J. Neurosci. 16 Suppl. 3 2009 460
28. K. Posner State of the Science: Measurement of Suicidal Adverse Events and the Columbia Suicide Severity Rating Scale 2007 NCDEU Boca Raton, FL
29. A.J. Rush, M.H. Trivedi, H.M. Ibrahim, T.J. Carmody, B. Arnow, D.N. Klein, J.C. Markowitz, P.T. Ninan, S. Kornstein, R. Manber, M.E. Thase, J.H. Kocsis, and M.B. Keller The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression Biol. Psychiatry 54 5 2003 573 583 (Pubitemid 37289444)
30. D.V. Sheehan The Anxiety Disease 1983 Charles Scribner & Sons New York, NY 151
31. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 Suppl 20 1998 22 33 (Pubitemid 29001829)
32. Suehs, B., Argo, T.R., Bendele, S.D., Crismon, M.L., Trivedi, M.H., Kurian, B., 2008. Texas medication algorithm project procedural manual: major depressive disorder algorithms. Texas Department of State Health Services. http://www.pbhcare.org/pubdocs/upload/documents/TMAP%20Depression%202010.pdf (accessed 08.05.14.).
33. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, M. Fava STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am. J. Psychiatry 163 1 2006 28 40 (Pubitemid 43050100)
34. J.B. Williams, K.A. Kobak, P. Bech, N. Engelhardt, K. Evans, J. Lipsitz, J. Olin, J. Pearson, and A. Kalali The GRID-HAMD: standardization of the Hamilton Depression Rating Scale Int. Clin. Psychopharmacol. 23 3 2008 120 129 (Pubitemid 351535903)
35. S.R. Wisniewski, M. Fava, M.H. Trivedi, M.E. Thase, D. Warden, G. Niederehe, E.S. Friedman, M.M. Biggs, H.A. Sackeim, K. Shores-Wilson, P.J. McGrath, P.W. Lavori, S. Miyahara, and A.J. Rush Acceptability of second-step treatments to depressed outpatients: a STAR*D report Am. J. Psychiatry 164 5 2007 753 760 (Pubitemid 46808530)
36. S.R. Wisniewski, A.J. Rush, A.A. Nierenberg, B.N. Gaynes, D. Warden, J.F. Luther, P.J. McGrath, P.W. Lavori, M.E. Thase, M. Fava, and M.H. Trivedi Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report Am. J. Psychiatry 166 5 2009 599 607
37. F. Wolfe Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients J. Rheumatol. 31 10 2004 1896 1902 (Pubitemid 39336711)
38. Yavorsky, C., Williams, J.B.W., 2009. Research assessment of depression diagnosis and severity: Comparability of telephone and in-person interview. In: Proceedings of the Poster presented at American Psychiatric Association 162nd Annual Meeting, May 20 2009 San Francisco, CA.
39. A.S. Zigmond, and R.P. Snaith The hospital anxiety and depression scale Acta. Psychiatr. Scand. 67 6 1983 361 370 (Pubitemid 13098606)